Regenerative medicine company PharmaResearch said it showcased its aesthetics solutions, including Rejuran, to global physicians and industry professionals.
The company announced on June 23 that it participated in AMWC Korea 2026 (Aesthetic & Anti-aging Medicine World Congress), held recently at Grand InterContinental Seoul Parnas in Seoul’s Gangnam district, where it presented a total aesthetics solution portfolio centered on Rejuran to domestic and international attendees.
AMWC is one of the world’s most prestigious international conferences in aesthetic medicine and anti-aging, serving as a platform for sharing the latest clinical experience and treatment trends. This year’s event marked the conference’s first edition in South Korea and attracted a large number of global medical professionals and industry stakeholders.
PharmaResearch highlighted its aesthetics portfolio built around Rejuran, a skin booster based on DOT PN (polynucleotide) extracted from salmon DNA. At its exhibition booth, the company also introduced key products including Cleviel hyaluronic acid filler, ReNTox botulinum toxin type A formulation, and Conjuran, a PN-based intra-articular injection, showcasing competitiveness across both aesthetic and therapeutic applications.
The company also received the Best Injectable for Skin Revitalization award selected by AMWC. PharmaResearch said the recognition reflects international acknowledgment of its regenerative medicine-based technology platform and its approach to well-aging centered on Rejuran.
The event also featured programs designed to expand the Rejuran brand experience. These included Rejumate, a dedicated injector for Rejuran treatments; the Rejuran Professional Care Program for medical institutions; and Rejuran Cosmetics. Together, the offerings present an integrated solution spanning treatment convenience, post-procedure care, and home skincare. The company said the portfolio underscores its competitiveness as a total aesthetics solution designed for both healthcare providers and consumers.
Image caption: PharmaResearch showcases its Rejuran-centered aesthetics portfolio at AMWC Korea 2026. (PharmaResearch)
Clinical sessions at the conference also explored Rejuran’s potential applications. Dr. Suneel Chilukuri, a U.S. board-certified dermatologist and authority in aesthetics, presented evidence-based perspectives on the mechanism of action and clinical use of polynucleotides. Dr. Park Hyun-jun of Cheongdam Maylin Clinic discussed strategies for improving enlarged pores, pigmentation, and facial redness through combined treatment using Rejuran and energy-based devices (EBDs).
“AMWC Korea was a meaningful opportunity to introduce PharmaResearch’s total aesthetics solutions directly to international medical professionals at a global conference being held in Korea for the first time,” a company official said. “Winning an AMWC award demonstrates international recognition of Rejuran’s competitiveness, and we will continue expanding research and academic exchanges to strengthen our brand presence in the global medical aesthetics market.”
Separately, Rejuran Cosmetics, the company’s premium derma-cosmetics brand, ranked No. 1 among K-beauty brands in Malaysia’s skincare category based on sales data compiled from June 1-4.